In recent years, inflammation has emerged as a significant risk factor in a range of human pathologies. While short-term acute inflammation both defends the body from pathogens and helps to preserve tissue homeostasis, chronic inflammation is characterized by the accumulation of inflammatory cells, excessive cytokine production, and the deregulation of cell signalling pathways. This type of inflammation has been linked to many diseases, including neurodegenerative, cardiovascular, and metabolic disorders. The immune system is responsible for defending the body against pathogens, but it also plays a critical role in maintaining metabolic homeostasis. Immune cells such as macrophages, T cells, and B cells are highly metabolic and require a constant supply of energy to perform their functions. Conversely, metabolic processes such as glucose and lipid metabolism have been shown to influence immune cell function and differentiation. There has been growing interest in the intersection of immunology and metabolism, and how these two fields can be leveraged to develop new therapeutic approaches for a variety of diseases including various inflammatory diseases. This has led to the emergence of the field of immunometabolism, which seeks to understand how metabolic processes influence immune cell function and vice versa.The goal of immunometabolism and pharmacology is to understand the complex interactions between the immune system and metabolic processes in the body, and to use this knowledge to develop new therapeutic approaches for a variety of diseases. This has important implications for the development of new therapeutic approaches for a variety of diseases, including autoimmune disorders, metabolic disorders, and cancer. By understanding the interactions between the immune system and metabolic processes, researchers in the field of immunometabolism and pharmacology hope to develop new drugs that target key metabolic pathways involved in immune cell activation and differentiation. This could lead to the development of new treatments for a variety of diseases, including autoimmune disorders, metabolic disorders, and cancer. Additionally, the field of immunometabolism and pharmacology seeks to identify biomarkers of drug response and toxicity in immunometabolic diseases, and to develop personalized medicine approaches for patients with these diseases. Overall, the goal is to improve our understanding of immunometabolism to develop safe and effective treatments for a range of inflammatory diseases.We are especially interested in, but not limited to, submissions focused on the following: 1. The impact of metabolic disorders, such as obesity and type 2 diabetes, on immune function and the potential for pharmacological interventions to improve immune function in these patients. 2. The use of immunometabolic profiling to identify new drug targets and predict drug responses in patients with autoimmune and inflammatory diseases. 3. The development of novel pharmacological agents that target key metabolic pathways involved in immune cell activation and differentiation. 4. The role of immune cells in drug metabolism and pharmacokinetics, and the potential for immune-modulating drugs to affect drug efficacy and toxicity. 5. The use of metabolomics and other omics approaches to identify biomarkers of drug response and toxicity in immunometabolic diseases. 6. The use of immunometabolic profiling to develop personalized medicine approaches for patients with inflammatory diseases. 7. The role of the gut microbiome in immune function and drug metabolism, and the potential for microbiome-targeted therapies to improve drug efficacy and safety.
In recent years, inflammation has emerged as a significant risk factor in a range of human pathologies. While short-term acute inflammation both defends the body from pathogens and helps to preserve tissue homeostasis, chronic inflammation is characterized by the accumulation of inflammatory cells, excessive cytokine production, and the deregulation of cell signalling pathways. This type of inflammation has been linked to many diseases, including neurodegenerative, cardiovascular, and metabolic disorders. The immune system is responsible for defending the body against pathogens, but it also plays a critical role in maintaining metabolic homeostasis. Immune cells such as macrophages, T cells, and B cells are highly metabolic and require a constant supply of energy to perform their functions. Conversely, metabolic processes such as glucose and lipid metabolism have been shown to influence immune cell function and differentiation. There has been growing interest in the intersection of immunology and metabolism, and how these two fields can be leveraged to develop new therapeutic approaches for a variety of diseases including various inflammatory diseases. This has led to the emergence of the field of immunometabolism, which seeks to understand how metabolic processes influence immune cell function and vice versa.The goal of immunometabolism and pharmacology is to understand the complex interactions between the immune system and metabolic processes in the body, and to use this knowledge to develop new therapeutic approaches for a variety of diseases. This has important implications for the development of new therapeutic approaches for a variety of diseases, including autoimmune disorders, metabolic disorders, and cancer. By understanding the interactions between the immune system and metabolic processes, researchers in the field of immunometabolism and pharmacology hope to develop new drugs that target key metabolic pathways involved in immune cell activation and differentiation. This could lead to the development of new treatments for a variety of diseases, including autoimmune disorders, metabolic disorders, and cancer. Additionally, the field of immunometabolism and pharmacology seeks to identify biomarkers of drug response and toxicity in immunometabolic diseases, and to develop personalized medicine approaches for patients with these diseases. Overall, the goal is to improve our understanding of immunometabolism to develop safe and effective treatments for a range of inflammatory diseases.We are especially interested in, but not limited to, submissions focused on the following: 1. The impact of metabolic disorders, such as obesity and type 2 diabetes, on immune function and the potential for pharmacological interventions to improve immune function in these patients. 2. The use of immunometabolic profiling to identify new drug targets and predict drug responses in patients with autoimmune and inflammatory diseases. 3. The development of novel pharmacological agents that target key metabolic pathways involved in immune cell activation and differentiation. 4. The role of immune cells in drug metabolism and pharmacokinetics, and the potential for immune-modulating drugs to affect drug efficacy and toxicity. 5. The use of metabolomics and other omics approaches to identify biomarkers of drug response and toxicity in immunometabolic diseases. 6. The use of immunometabolic profiling to develop personalized medicine approaches for patients with inflammatory diseases. 7. The role of the gut microbiome in immune function and drug metabolism, and the potential for microbiome-targeted therapies to improve drug efficacy and safety.